Delving into the Latest Updates on Linrodostat with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Linrodostat (USAN), Linrodostat mesylate, BMS-986205

+ [5]

Target

IDO1

Action

inhibitors

Mechanism

IDO1 inhibitors(Indoleamine 2,3-dioxygenase inhibitors)

Therapeutic Areas

NeoplasmsMouth and Tooth DiseasesOtorhinolaryngologic Diseases+ [3]

Active Indication

CarcinosarcomaRecurrent Endometrial CancerUterine Carcinosarcoma+ [6]

Inactive Indication

Acral Lentiginous Malignant MelanomaAdvanced gastric carcinomaAdvanced Lung Non-Small Cell Carcinoma+ [11]

Originator Organization

Bristol Myers Squibb Co.

Active Organization

Bristol Myers Squibb Co.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC24H24ClFN2O

InChIKeyKRTIYQIPSAGSBP-ZACQAIPSSA-N

CAS Registry1923833-60-6

This phase I trial studies the side effects of nivolumab, BMS-986205, and standard radiation therapy with or without temozolomide in treating patients with new diagnosed glioblastoma. Immunotherapy with nivolumab, may induce changes in body?s immune system and may interfere with the ability of tumor cells to grow and spread. BMS-986205 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and BMS-986205 may work better compared to radiation therapy and temozolomide alone in treating patients with newly diagnosed glioblastoma.

Start Date13 Aug 2019

Sponsor / Collaborator

Northwestern University

[+1]

100 Clinical Results associated with Linrodostat

Login to view more data

100 Translational Medicine associated with Linrodostat

Login to view more data

100 Patents (Medical) associated with Linrodostat

Login to view more data

55

Literatures (Medical) associated with Linrodostat

08 Apr 2026·BIOCHEMICAL JOURNAL

Artemether and Euphorbia factor L9 suppress kynurenine production through distinct effects on tryptophan metabolism

Article

Author: Plunkett-Jones, Charlotte ; Capatina, Alina L. ; Brackenbury, William J. ; Graham, Ian A. ; Tonon, Thierry ; Lagos, Dimitris ; Czechowski, Tomasz ; Lichman, Benjamin R. ; Kourtzelis, Ioannis

Abstract:

l-Tryptophan (Trp) is an essential amino acid catabolised through the kynurenine pathway, which is mediated by the enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2, or Trp-2,3-deoxygenase. In cancer, IDO1 acts as an immune checkpoint, suppressing effector T cell function. Yet, direct inhibition of IDO1 has had limited success in clinical trials. Therefore, alternative approaches to Trp metabolism therapeutic targeting are needed. We screened a library of 597 natural products (NPs) or NP derivatives for their effect on kynurenine production in triple-negative breast cancer cells. This revealed 24 candidate inhibitors of kynurenine production. Among them, artemether, a member of the artemisinin family of anti-malarial drugs, suppressed kynurenine production, likely via an endoperoxide bridge-dependent mechanism. The Euphorbia factor L9 (EFL9) inhibited kynurenine production, likely via a C7-benzoylation-dependent mechanism. Neither artemether nor EFL9 affected JAK/STAT signalling or IDO1 levels. Targeted metabolomics and molecular docking analyses demonstrated that artemether suppressed kynurenine production through heme sequestration and potential interactions with the IDO1 heme-binding pocket A. EFL9 affected Trp metabolism through heme-independent mechanisms and resulted in changes in purine and amino acid metabolism and the cellular redox balance. Notably, ouabain, a regulator of IDO1 levels, and linrodostat, a clinically approved IDO1 inhibitor, revealed distinct metabolic profiles, with ouabain and EFL9 showing the largest overlap. Importantly, the kynurenine-suppressing activities of artemether and EFL9 were observed in non-transformed primary mammary epithelial cells and also lung cancer cells. Overall, our findings set the foundation for future studies exploring the use of artemether or EFL9 as novel Trp metabolism-targeting therapeutics.

01 Mar 2026·ESMO Open

Fast Real-Time Assessment of Combination Therapies in Immuno-ONcology in patients with advanced non-small-cell lung cancer (FRACTION-Lung)

Article

Author: Govindan, R ; Juergens, R A ; Spigel, D R ; Santoro, A ; Spira, A ; Laurie, S A ; Greenawalt, D M ; Schoenfeld, A J ; Zinner, R ; Forde, P M ; Chu, Q ; Camidge, D R ; He, K ; Gettinger, S ; Cerra, M ; Rapoport, I ; Gainor, J F ; Borghaei, H ; Gurpide, A ; Spires, T

BACKGROUND:

The phase II FRACTION-Lung platform trial (NCT02750514) aimed to evaluate novel immunotherapy combinations in advanced non-small-cell lung cancer (aNSCLC).

PATIENTS AND METHODS:

Adults with aNSCLC and Eastern Cooperative Oncology Group performance status ≤1 were allocated to tracks 1 to 5 based on programmed cell death protein (ligand) 1 [PD-(L)1] status and/or prior receipt of anti-PD-(L)1 therapy, and received nivolumab (anti-PD-1) as monotherapy or combination therapy [dasatinib (multi-kinase inhibitor), ipilimumab (anti-CTLA-4), relatlimab (anti-LAG-3), or linrodostat (IDO1 inhibitor)]. Patients with progression in one arm could be re-randomized. Primary endpoints were objective response rate (ORR); duration of response (DOR); and 24-week progression-free survival (PFS) rate. Safety was a secondary endpoint; biomarker analyses were exploratory.

RESULTS:

Overall, 295 patients were treated (191 received no prior immunotherapy, 118 received prior immunotherapy; 14 were re-randomized assigned). Among patients without prior immunotherapy, ORRs ranged from 0% (multiple arms) to 25% (nivolumab plus ipilimumab: 3/12 patients; nivolumab plus dasatinib: 1/4 patients), and among patients with prior immunotherapy from 2.3% (nivolumab plus linrodostat: 1/43 patients) to 5.6% (nivolumab plus ipilimumab: 1/18 patients). Median DOR was not estimated due to limited tumor responses. Twenty-four-week PFS rates ranged from 30.2% [nivolumab-only (n = 40)] to 45.5% [nivolumab plus ipilimumab (n = 12)] among patients without prior immunotherapy and 11.1% [nivolumab plus linrodostat (n = 43)] to 19.1% [nivolumab plus dasatinib (n = 41)] among patients with prior immunotherapy. No new safety signals were observed. Small sample sizes in each treatment group limited analyses, including biomarkers. The study was discontinued early due to an evolving treatment landscape and limited efficacy signals. Given the rolling, adaptive design, this trial was not statistically powered to assess treatment benefits and draw definitive efficacy conclusions, as early termination and the changing standard of care limited accrual.

CONCLUSIONS:

Despite limited efficacy, the innovative adaptive trial design allowed rapid evaluation of multiple regimens, which may inform future trials.

01 Dec 2025·CELL DEATH AND DIFFERENTIATION

Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes

Article

Author: Graumann, Johannes ; Teply-Szymanski, Julia ; Pfisterer, Maximilian ; Schmitz, Roland ; Bartkuhn, Marek ; van den Borre, David ; Wilhelm, Jochen ; Nist, Andrea ; Huck, Michael ; Ndreshkjana, Benardina ; Klatt, Stephan ; Schmitz, M Lienhard ; Beutgen, Vanessa M ; Leff, Chloe ; Farin, Henner F ; Gärtner, Ulrich ; Stiewe, Thorsten ; Stengel, Julia ; Dreute, Jan ; Becher, Jonas ; Cabrera-Orefice, Alfredo

Abstract:

As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, BMS-986205, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), also restricts oxidative phosphorylation (OXPHOS), as revealed here. BMS-986205, which is being tested in multiple Phase III clinical trials, inhibits the ubiquinone reduction site of respiratory complex I and thus compromises mitochondrial ATP production. The energetic catastrophe caused by simultaneous interference with glycolysis and OXPHOS resulted in either cell death or the induction of senescence in tumor cells, with the latter being eliminated by senolytics. The frequent synergy observed with combined inhibitor treatment was comprehensively confirmed through testing on tumor cell lines from the DepMap panel and on human colorectal cancer organoids. These experiments revealed highly synergistic activity of the compounds in a third of the tested tumor cell lines, correlating with alterations in genes with known roles in metabolic regulation and demonstrating the therapeutic potential of metabolic intervention.

8

News (Medical) associated with Linrodostat

28 Nov 2022

·www.businesswire.com

2022 Bladder Cancer Update Bulletin: Key Opinion Leader (KOL) Views on Recent Developments - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Bladder Cancer: Update Bulletin #2" newsletter has been added to ResearchAndMarkets.com's offering. This edition presents leading key opinion leader (KOL) views on recent developments in the Bladder Cancer market. Topics covered include: Bristol-Myers Squibb (BMS) presenting positive data from a Phase I/II study investigating a combination of its PD-1 inhibitor Opdivo (nivolumab) with its pipeline indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, BMS-986205, in heavily pretreated patients with advanced bladder cancer; BioCanCell announcing final results for its Phase IIb combination trial investigating its lead compound BC-819 in combination with the BCG vaccine in 38 patients with intermediate-and high-risk non-muscle invasive bladder cancer (NMIBC); KOLs offering their updated opinions on the the supply status of the BCG vaccine in the US and key European markets. Business Questions: How do the KOLs perceive the Phase II combination results for BMS' Opdivo with the IDO inhibitor BMS-986205 in patients with advanced bladder cancer? Do KOLs view PD-1/PD-L1 and IDO inhibition as a viable combination approach going forward? What are experts' thoughts on PD-L1 expression and its future use as a biomarker in patients with bladder cancer? Do KOLs hold any other concerns about dual immunotherapy combinations such as cost, access or increased risk of toxicity? If approved, how and when would KOLs consider using the combination approach of Opdivo with an IDO inhibitor? Based on published Phase II data, how do the experts view the results so far for BC-819 with BCG in patients with NMIBC? Are the KOLs enthusiastic about intravesical gene therapies as treatments for NMIBC and if so, why? How do the experts perceive the planned Phase III trial investigating BC-819 in patients that are BCG-recurrent? If approved, can BC-819 gain market share in patients with high-risk or intermediate-risk NMIBC? What are KOLs' opinions on the supply shortages previously reported for the BCG vaccine and are they being addressed? For more information about this newsletter visit https://www.researchandmarkets.com/r/9ke1kl

Phase 2VaccineImmunotherapyClinical ResultASCO

09 Feb 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

27 Jan 2021

·www.globenewswire.com

Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows

Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively involved in developing novel therapies for Non-Muscle Invasive Bladder Cancer (NMIBC) and over 30+ therapies expected to get launched, Non-Muscle Invasive Bladder Cancer Pipeline presents quite a promising overall picture for the next decade. “Non-Muscle Invasive Bladder Cancer (NMIBC) Pipeline Insight, 2021” by DelveInsight highlights the details around the NMIBC pipeline scenario, unmet needs, and Non-Muscle Invasive Bladder Cancer therapeutic assessment of the key pipeline therapies. Some of the key Non-Muscle Invasive Bladder Cancer Pipeline Highlights: Non-Muscle Invasive Bladder Cancer is a common, heterogeneous cancer found in the tissue of the bladder's inner surface, wherein the bladder muscle is not involved. NMIBC Pipeline Therapies Opdivo: Bristol-Myers Squibb/Ono Pharmaceuticals Opdivo (Nivolumab) is a programmed death-1 (PD-1) immune checkpoint inhibitor developed by Bristol-Myers Squibb. The drug harnesses the body’s immune system to help restore anti-tumor immune response by blocking the interaction between PD-1 and its ligands. Opdivo holds a vital place as the treatment option across multiple cancers. It has been approved for colorectal cancer; gastric cancer; Head and neck cancer; Hodgkin's disease; Liver cancer; Malignant melanoma; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer, and is currently in phase III clinical development for participants with High-risk Non-muscle Invasive Bladder Cancer that is persistent or recurrent after treatment with BCG in a phase III trial titled “a phase III, randomized, double-blind trial of Nivolumab in combination with Intravesical BCG Versus Standard of Care BCG alone’’ (NCT04149574). The trial is currently in the recruiting stage with an estimated enrollment of 700 participants and expected to be completed in August 2030. BMS is also evaluating Opdivo in a phase II trial titled “a phase II, randomized, open-label study of Nivolumab or Nivolumab/BMS-986205 alone or combined with intravesical BCG in participants with BCG-Unresponsive, high-risk, Non-Muscle Invasive Bladder Cancer” (NCT03519256). The trial is currently in the recruiting stage with an estimated enrollment of 358 participants and expected to be completed in September 2024. UGN-102: UroGen Pharma UGN-102 (mitomycin gel) is an investigational formulation that utilizes innovative technology, RTGel reverse-thermal hydrogel, for the treatment of low-grade NMIBC. UroGen Pharma is investigating the therapy in phase 3, to assess the long-term efficacy and safety of UGN-102 (mitomycin) for an intravesical solution with or without (±) transurethral resection of bladder tumors. The trial is currently in the recruiting stage with an estimated enrolment of 632 participants and expected to be completed in December 2023. Atezolizumab: Hoffmann-La Roche Roche’s Atezolizumab (Tecentriq), a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, is already commercially available for Breast cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Small cell lung cancer; and Urogenital cancer. Roche is also evaluating the drug for Non-Muscle Invasive Bladder Cancer. It is currently in the recruiting stage with an estimated enrollment of 614 participants and expected to be completed in February 2028. To learn more about NMIBC Drugs Development, request NMIBC Drugs Pipeline Sample Report Scope of Non-Muscle Invasive Bladder Cancer Pipeline Report Coverage: Global Major Players: 30+ companiesProminent Players: Bristol-Myers Squibb, Ono Pharmaceuticals, Pfizer, Merck Sharp & Dohme Corp., Ferring Pharmaceuticals, UroGen Pharma, Roche, Viventia Bio, ImmunityBioKey Drugs: 30+ pipeline drugsNon-Muscle Invasive Bladder Cancer Therapies: Atezolizumab, ALT-803, UGN-102, Vicinium, Nivolumab, Pembrolizumab, PF-06801591, Durvalumab, APL-1202Phases Targets Mechanism of Action Molecule Types Route of Administration Product Types Visit to know more about the report offerings @ Non-Muscle Invasive Bladder Cancer Emerging Therapies Key Questions Answered in Non-Muscle Invasive Bladder Cancer Pipeline Report Get in touch with our Business Executive @ NMIBC Pipeline Trends and Futuristic Outlook to learn more about the domain. Table of Contents Related Reports Bladder Cancer Market DelveInsight's "Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Bladder cancer, historical and forecasted epidemiology as well as the Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Muscle Invasive Bladder Cancer Market DelveInsight's "Muscle Invasive Bladder Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer Non-Muscle Invasive Bladder Cancer Market DelveInsight’s ‘Non-muscle Invasive Bladder Cancer (NMIBC)—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the NMIBC, historical and forecasted epidemiology as well as the NMIBC market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Multiple Myeloma Market DelveInsight’s ‘Multiple Myeloma (MM) Market Insights, Epidemiology and Market Forecast—2030’ report delivers an in-depth understanding of the MM, historical and forecasted epidemiology as well as the MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Japan and China. Non-Small Cell Lung Cancer Market DelveInsight’s ‘Non-Small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology and Market Forecast - 2030’ report delivers an in-depth understanding of the Non-Small Cell Lung Cancer, historical and forecasted epidemiology as well as the Non-Small Cell Lung Cancer market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), and Japan. Prostate Cancer Market DelveInsight's "Prostate cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Prostate cancer, historical and forecasted epidemiology as well as the Prostate cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Adenoid Cystic Carcinoma Market DelveInsight's "Adenoid Cystic Carcinoma Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Adenoid Cystic Carcinoma, historical and forecasted epidemiology as well as the Adenoid Cystic Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Liver Cancer Market DelveInsight's "Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Liver Cancer, historical and forecasted epidemiology as well as the Advanced Liver Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Advanced Pancreatic Cancer Market DelveInsight's "Advanced Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Advanced Pancreatic Cancer, historical and forecasted epidemiology as well as the Advanced Pancreatic Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Pancreatic Adenocarcinoma Market DelveInsight's "Pancreatic Adenocarcinoma - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Pancreatic Adenocarcinoma, historical and forecasted epidemiology as well as the Pancreatic Adenocarcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

CollaborateAntibody

100 Deals associated with Linrodostat

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11412	-	-	DB14986

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Non-Small Cell Lung Cancer	Phase 3	United States	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	United States	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Japan	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Australia	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Austria	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Brazil	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Canada	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Czechia	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	France	Bristol Myers Squibb Co.	24 May 2018
Recurrent Non-Small Cell Lung Cancer	Phase 3	Germany	Bristol Myers Squibb Co.	24 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03459222 (RELATIVITY-048, CTgov)	Phase 1/2	Solid tumor \| Advanced cancer	229	Nivolumab+Relatlimab+BMS-986205 (1A-esc-480/160/25)	rxvyljtdnx = vkretkrbpv aqffedcahl (rdrhrxmtha, knjzhhvuok - cueuqagwcj) View more	-	06 Apr 2026
				Nivolumab+Relatlimab+BMS-986205 (1A-esc-480/160/50)	rxvyljtdnx = wvulkbidkj aqffedcahl (rdrhrxmtha, kgmbchjgmq - dobdxhymdq) View more
NCT03695250 (CTgov)	Phase 1/2	Unresectable Hepatocellular Carcinoma \| Metastatic hepatocellular carcinoma	8	Nivolumab+IDO1 Inhibitor BMS-986205	zpefhcezou = cmvmuhvfqa tqzzsjelub (tizxjvutqb, omxzsjtror - kmvywvwcdh) View more	-	22 Aug 2023
NCT03519256 (CheckMate 9UT, CTgov)	Phase 2	Non-Muscle Invasive Bladder Neoplasms	142	Nivolumab (Arm A: Nivolumab)	ouldvqeadi = ubcilzfukr cuygnjpaig (hlbqmrclyz, fcrctkzdei - mlckmncdte) View more	-	01 Jun 2023
				BCG+Nivolumab (Arm B: Nivolumab Plus Intravesical BCG)	ouldvqeadi = tlmgjfqlix cuygnjpaig (hlbqmrclyz, pevhnmnjdy - hieejddmiy) View more
NCT03854032 (CA017-087, ASCO2022) Manual	Phase 2	Squamous Cell Carcinoma of Head and Neck Neoadjuvant	42	nivolumab	afeatrjxkt(rnrjvklcwb) = ehwkiqaist kdnxjkhilp (jzyifdzfmf )	Non-superior	02 Jun 2022
				Nivolumab+Linrodostat	afeatrjxkt(rnrjvklcwb) = lcwhaeiyjv kdnxjkhilp (jzyifdzfmf )
NCT04106414 (CA017-056, ASCO2022) Manual	Phase 2	Recurrent Endometrial Cancer Maintenance	24	Nivolumab + BMS-986205	svnatsetmt(xeicvvrbjr) = bcfofvnxwp lnqezangfl (vnngjethgi, 0.9 - 100) View more	Negative	02 Jun 2022
				Nivolumab	svnatsetmt(xeicvvrbjr) = qzufwzmdwq lnqezangfl (vnngjethgi ) View more
NCT03695250 (ASCO2022)	Phase 1/2	Hepatocellular Carcinoma First line	8	BMS-986205 + Nivolumab	yszvtfkpcx(jyesuynerl) = alsctlcrnx xaauywfvxt (lvpegwvsym ) View more	Positive	02 Jun 2022
NCT03792750 (CTgov)	Phase 1/2	Advanced Malignant Solid Neoplasm \| Advanced cancer	12	Nivolumab+BMS-986205 (BMS-986205 in Combination With Nivolumab)	kavjzgbkgp = jgynclxdal apfpodbcxc (ehydmjhlwt, plxivcpxdm - tzgoihmkqk) View more	-	28 Feb 2022
				Nivolumab+BMS-986205 (BMS-986205 Monotherapy and in Combination With Nivolumab)	dbxggeomkk = ikmbtjwerx qahxfagniu (hrhlwhhhbv, tahltyoiyb - gpmoaozmad) View more
NCT03329846 (CTgov)	Phase 3	Unresectable Melanoma	20	Nivolumab+BMS-986205	tzduxhwqjj = hcivovnrxi azecgwxfrm (shtcpuafms, luehzsyumw - bfdhtoduww) View more	-	09 Jul 2021
NCT02658890 (ASCO_GU 12019 \| ASCO_GU 22019) Manual	Phase 1/2	Bladder Cancer	516	BMS-986205+nivolumab	opacaherxi(gssnqajwub) = gbdnghtgxn cmybrigxlm (ajmxiuvydw ) View more	Positive	15 Feb 2019
NCT02658890 (BMS-986205, SITC2017)	Phase 1/2	Advanced cancer kynurenine	216	BMS-986205 100 mg + Nivolumab 240 mg	gvkgxthcsu(zdrjlxhgia) = dutikhoiud privxnwjxo (ddpptavvlx ) View more	Positive	07 Dec 2017
				BMS-986205 200 mg + Nivolumab 480 mg	gvkgxthcsu(zdrjlxhgia) = veaghcjgav privxnwjxo (ddpptavvlx ) View more